Johnson & Johnson's earnings call highlights strong operational sales growth despite macroeconomic headwinds and currency fluctuations.  Management emphasized continued investment in R&D, dividend increases, and share repurchases, showcasing the company's financial resilience.  Guidance for 2023 anticipates 4.5-5.5% sales growth and modest adjusted earnings per share growth, however tempered by concerns of STELARA loss of exclusivity and some lingering COVID-related effects in China, suggesting slight near-term pressure but no immediate significant threat.

[1]
